Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: BD, Carestream Dental, Cue Health, Envista, Everly Health, Ixensor, Lucira, Nevro, Nalu.
Becton, Dickinson and Co. (BD) completed its acquisition of Scanwell Health Inc., its partner in development of the smartphone-enabled BD Veritor At-Home COVID-19 Test, just in time for increased demand driven by the Omicron surge in the U.S. and plans to make the tests available for free by the federal government as well as several states and large municipalities. Currently, most of the tests distributed by governments are made by Abbott Laboratories, which received emergency use authorization (EUA) for its at-home test in March 2021.
As the Omicron variant of COVID-19 sweeps across the globe, the Biden administration has announced a program to purchase 500 million rapid antigen tests to help slow the pandemic. The news comes at an especially critical time, given the increased transmissibility of the Omicron variant, but the promised volume is unlikely to be achieved by the first day of January 2022.
Bond Digital Health Ltd. landed £1 million (US$1.3 million) from investors to expand development of its Transform data management system for lateral flow diagnostic tests. The technology connects to an app that captures data from lateral flow assays in self-testing settings. The results are then shared to a dashboard that can be monitored by the platform admin. The new investment included equity funding from the Development Bank of Wales and high-net-worth investment service Wealth Club. In addition to the current round, Bond is aiming to raise a further £500,000 by January.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affera, Cytosorbents, Magforce, Vesper, Xeltis, Zynex.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Firstkind, Implicity, Roche, Sky Medical Technology.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Applied Biocode, Fist Assist, Mdoloris, Mindray.
Xandar Kardian Inc. closed a $10 million series A funding round to support the rollout of the company’s contactless health monitoring solution. Phoenix Venture Partners led the round with participation from Portfolia Active Aging & Longevity Fund, Taronga Ventures and others. “With the new financing round, Xandar Kardian looks forward to expanding its core team in Toronto and in the United States, in addition to placing increased emphasis on R&D and mass production for its technologies,” Xandar Kardian co-founder and CEO Sam Yang told BioWorld.
RSS
